publication date: Sep. 6, 2019

NCI Director’s Report

Lowy: NCI needs 15% budget increase to reach FY2021 goal of 15th percentile for paylines

By Matthew Bin Han Ong

NCI is requesting an increase of $989 million to its FY2021 budget over FY2019 appropriated levels to boost the institute’s payline, which has dropped to the 8th percentile in FY19—lower than 2013 sequestration levels—and which has been steadily dropping despite increased overall funding in recent years.

According to NCI’s latest Annual Plan and Budget Proposal, also known as a “bypass budget,” the institute is asking Congressional appropriators and the White House to increase its base budget by nearly $1 billion, from $5.744 billion to $6.733 billion by FY21. Combined with $195 million in Cancer Moonshot funding for that year, NCI’s proposed total budget for FY21 is $6.928 billion.

Established under the National Cancer Act of 1971, the bypass budget authority requires the NCI director to inform the president and Congress directly, bypassing NIH and HHS, about opportunities in cancer research. This professional judgment budget isn’t a part of the appropriations process.

“We’re making a proposal for a substantial increase for 2021 compared to 2019, and even the markup for 2020, because we would need a substantial increase of at least 15% for the budget, in order to try to get to a 15th percentile payline,” NCI Acting Director Douglas Lowy said at a Sept. 4 meeting of the National Cancer Advisory Board.

“There has been an increase in the number of average number of applications, about 15% increase over the last five years. There also has been a substantial increase in the number of applications in response to program announcements with review. And … Continue reading Lowy: NCI needs 15% budget increase to reach FY2021 goal of 15th percentile for paylines

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.